Ex vivo micro-computed tomography analysis of bleomycin-induced lung fibrosis for preclinical drug evaluation

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1633-1645

  Scotton, Chris J ^a   Hayes, Brian ^b   Alexander, Robert ^a   Datta, Arnab ^a   Forty, Ellen J ^a   Mercer, Paul F ^a   Blanchard, Andy ^b   Chambers, Rachel C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; PROTEIN KINASE INHIBITOR; SB 525334A; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; LUNG WEIGHT; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONTENT; QUALITY CONTROL; SIGNAL TRANSDUCTION; VALIDATION STUDY;

ANIMALS; BLEOMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FIBROSIS; HUMANS; IMIDAZOLES; LUNG; MALE; MICE; MICE, INBRED C57BL; PROTEIN-SERINE-THREONINE KINASES; PULMONARY FIBROSIS; QUINOXALINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

EID: 84890072356     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00182412     Document Type: Article

References (30)

1. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972.
2. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011; 163: 141-172.
3. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382.
4. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294: L152-L160.
5. Scotton CJ, Chambers RC. Bleomycin revisited: towards a more representative model of IPF?Am J Physiol Lung Cell Mol Physiol 2010; 299: L439-L441.
6. Kakugawa T, Mukae H, Hayashi T, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004; 24: 57-65.
7. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
8. Aono Y, Nishioka Y, Inayama M, et al. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005; 171: 1279-1285.
9. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 173: 769-776.
10. Scotton CJ, Krupiczojc MA, Königshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550-2563.
11. Vasilescu DM, Knudsen L, Ochs M, et al. Optimized murine lung preparation for detailed structural evaluation via micro-computed tomography. J Appl Physiol 2012; 112: 159-166.
12. Grygielko ET, Martin WM, Tweed C, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005; 313: 943-951.
13. Iyer SN, Margolin SB, Hyde DM, et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998; 24: 119-132.
14. McGrath EE, Millar AB. Hot off the breath: triple therapy for idiopathic pulmonary fibrosis - hear the PANTHER roar. Thorax 2012; 67: 97-98.
15. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebocontrolled trial results. Am J Respir Crit Care Med 2010; 181: 604-610.
16. Wielpütz MO, Eichinger M, Zhou Z, et al. In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography. Eur Respir J 2011; 38: 1060-1070.
17. Babin AL, Cannet C, Gérard C, et al. Noninvasive assessment of bleomycin-induced lung injury and the effects of short-term glucocorticosteroid treatment in rats using MRI. J Magn Reson Imaging 2011; 33: 603-614.
18. Bartling SH, Kuntz J, Semmler W. Gating in small-animal cardio-thoracic CT. Methods 2010; 50: 42-49.
19. Hsia CC, Hyde DM, Ochs M, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010; 181: 394-418.
20. Thiesse J, Namati E, Sieren JC, et al. Lung structure phenotype variation in inbred mouse strains revealed through in vivo micro-CT imaging. J Appl Physiol 2010; 109: 1960-1968.
21. Ask K, Labiris R, Farkas L, et al. Comparison between conventional and "clinical" assessment of experimental lung fibrosis. J Transl Med 2008; 6: 16.
22. Rodt T, von Falck C, Dettmer S, et al. Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-β1. Respir Res 2010; 11: 181.
23. Lee HJ, Goo JM, Kim NR, et al. Semiquantitative measurement of murine bleomycin-induced lung fibrosis in in vivo and postmortem conditions using microcomputed tomography: correlation with pathologic scores - initial results. Invest Radiol 2008; 43: 453-460.
24. Jin GY, Bok SM, Han YM, et al. Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: assessed by micro-computed tomography and pathologic scores. Eur J Radiol 2012; 81: 1901-1906.
25. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005; 171: 889-898.
26. Higashiyama H, Yoshimoto D, Kaise T, et al. Inhibition of activin receptor-like kinase 5 attenuates bleomycininduced pulmonary fibrosis. Exp Mol Pathol 2007; 83: 39-46.
27. Lareu RR, Zeugolis DI, Abu-Rub M, et al. Essential modification of the Sircol Collagen Assay for the accurate quantification of collagen content in complex protein solutions. Acta Biomater 2010; 6: 3146-3151.
28. Chung MP, Monick MM, Hamzeh NY, et al. Role of repeated lung injury and genetic background in bleomycininduced fibrosis. Am J Respir Cell Mol Biol 2003; 29: 375-380.
29. Lawson WE, Polosukhin VV, Stathopoulos GT, et al. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am J Pathol 2005; 167: 1267-1277.
30. Degryse AL, Tanjore H, Xu XC, et al. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010; 299: L442-L452.